Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atabecestat in asymptomatic at-risk Alzheimer's
NCT02569398Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2015
- Primary completion
- Dec 2018
- Modality
- Orthosteric Ligands
- Countries
- 13
01
Overview
A Phase 3 trial of atabecestat in Alzheimer's disease (AD), sponsored by Janssen Pharmaceutical. Started Oct 2015; status: terminated.
02
Drugs
atabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02569398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02569398.